PT - JOURNAL ARTICLE AU - Chang, Chih-Chao AU - Vlad, George AU - Vasilescu, Elena Rodica AU - Li, Ping AU - Husain, Syed A. AU - Silvia, Elaine A. AU - Cohen, David J AU - Ratner, Lloyd E. AU - Sun, Wei-Zen AU - Mohan, Sumit AU - Suciu-Foca, Nicole TI - Previous SARS-CoV-2 infection or a third dose of vaccine elicited cross-variant neutralizing antibodies in vaccinated solid organ transplant recipients AID - 10.1101/2022.04.13.22273829 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.13.22273829 4099 - http://medrxiv.org/content/early/2022/04/18/2022.04.13.22273829.short 4100 - http://medrxiv.org/content/early/2022/04/18/2022.04.13.22273829.full AB - The SARS-CoV-2 pandemic poses a great threat to global health, particularly in solid organ transplant recipients (SOTRs). Although a 3-dose mRNA vaccination protocol has been implemented for the majority of SOTRs, its effectiveness was still largely unknown. We analyzed 113 vaccinated SOTRs, and 30 healthy controls (HCs), some of whom had recovered from COVID, for their immune responses against the original vaccine strain and variants of concern (VOC), including the highly mutated-omicron variant. Here, we report that 3 doses of the mRNA vaccine had only a modest effect in eliciting anti-viral responses against all viral strains in the fully vaccinated SOTRs who did not contract the virus. Only 34.0% (16/47) of this group of patients demonstrated both detectable anti-RBD IgG and neutralization activities against alpha, beta, and delta variants, and only 8.5% (4/47) of them showed additional omicron-neutralizing capacities. In contrast, 79.5% (35/44) of the vaccinated recovered-SOTRs demonstrated both higher anti-RBD IgG levels and neutralizing activities against all VOC, including omicron. These findings illustrate a significant impact of previous infection on the development of anti-COVID immune responses in vaccinated SOTRs and highlight the need for alternative strategies to protect a subset of a lesser-vaccine responsive population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was supported by intramural research programs of Department of Pathology and Cell Biology, Columbia UniversityAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This retrospective study was approved by a protocol (AAAT3602) from Institutional Review Board at Columbia University Irving Medical Center. Authorization for use of de-identified specimens from clinical care that would otherwise discarded. Use of de-identified lab results were approved by a waiver AAAP2200 through a HIPPA Guideline.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsSOTRsolid organ transplant recipientHChealthy controlSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2COVID-19coronavirus disease 2019VOCvariant of concernRT-PCRReal-Time polymerase chain reactionRBDreceptor binding domainMFImean fluorescence intensityIC50the half maximal inhibitory concentrationIQRinterquartile range